非酒精性脂肪性肝病分级分期管理研究进展

doi:10.3969/j.issn.1672-5069.2019.02.036

摘要/Abstract

摘要： 非酒精性脂肪性肝病（NAFLD）是代谢综合征在肝脏的病理学表现。由于饮食结构的改变,NAFLD发病率呈现上升趋势,且NAFLD与肝病进展、糖尿病和心血管疾病死亡密切相关。因此,寻求NAFLD患者综合管理方法迫在眉睫。本文综述了NAFLD分级、分期、治疗和随访评估的研究进展,以期指导临床诊断、治疗和管理。

关键词: 非酒精性脂肪性肝病, 分级, 管理

Abstract: Nonalcoholic fatty liver disease （NAFLD） is the pathological manifestation of metabolic syndrome in the liver. The morbidity rate of NAFLD in China is increasing,and NAFLD is closely related to the progression and mortality of liver disease and the morbidity of diabetes and cardiovascular disease. Therefore,it is urgent to seek a comprehensive management of patients with NAFLD. In this paper,we reviewed the NAFLD classification,staging,treatment and follow-up evaluation,in order to guide clinical practice.

Key words: Non-alcoholic fatty liver disease, Grade, Management

苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.

Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.

参考文献

[1] Rockey DC,Bell PD,Hill JA.Fibrosis-a common pathway to organ injury and failure. N Engl J Med,2015,372(12):1138-1149.
[2] Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol,2013,28(Suppl 1):11-17.
[3] Matteoni CA,Younossi ZM,Gramlich T,et al.Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity. Gastroenterology,1999,116(6):1413-1419.
[4] Blond E,Disse E,Cuerq C,et al.EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people:do they lead to over-referral Diabetologia,2017,60(7):1218-1222.
[5] 信丰智,范建高.欧洲非酒精性脂肪性肝病诊疗指南简介. 实用肝脏病杂志,2016,19(4):ⅤⅡ-ⅤⅢ.
[6] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2017[ahead of print].
[7] Rinella ME,Sanyal AJ.Management of NAFLD:a stage-based approach. Nat Rev Gastroenterol Hepatol,2016,13(4):196-205.
[8] Castera L,Vilgrain V,Angulo P.Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol,2013,10(11):666-675.
[9] Sasso M,Beaugrand M,de Ledinghen V,et al. Controlled attenuation parameter(CAP):a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis:preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol,2010,36(11):1825-1835.
[10] de Ledinghen V,Vergniol J,Foucher J,et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int,2012,32(6):911-918.
[11] Shen F,Zheng RD,Mi YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol,2014,20(16):4702-4711.
[12] Kumar M,Rastogi A,Singh T,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis:does etiology affect performance J Gastroenterol Hepatol,2013,28(7):1194-1201.
[13] Imajo K,Kessoku T,Honda Y,et al.Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology,2016,150(3):626-637.
[14] Lupsor-Platon M,Feier D,Stefanescu H,et al.Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis:a prospective study. J Gastrointestin Liver Dis,2015,24(1):35-42.
[15] Yoneda M,Yoneda M,Mawatari H,et al.Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease(NAFLD). Dig Liver Dis,2008
40(5):371-378.
[16] Wong VW,Vergniol J,Wong GL,et al.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology,2010,51(2):454-462.
[17] Lupsor M,Badea R,Stefanescu H,et al.Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis,2010,19(1):53-60.
[18] Gaia S,Carenzi S,Barilli AL,et al.Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol,2011,54(1):64-71.
[19] Wong VW,Vergniol J,Wong GL,et al.Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol,2012,107(12):1862-1871.
[20] Kumar R,Rastogi A,Sharma M K,et al.Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease:diagnostic performance and clinicopathological correlation. Dig Dis Sci,2013,58(1):265-274.
[21] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版). 实用肝脏病杂志,2018,21(2):177-186.
[22] Glen J,Floros L,Day C,et al.Non-alcoholic fatty liver disease (NAFLD):summary of NICE guidance. BMJ,2016,354:i4428.
[23] Singh S,Allen AM,Wang Z,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol,2015,13(4):643-654,e39-e40.
[24] Adams LA,Lymp JF,St S J,et al.The natural history of nonalcoholic fatty liver disease:a population-based cohort study. Gastroenterology,2005,129(1):113-121.
[25] Yasutake K,Nakamuta M,Shima Y,et al.Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease:the significance of dietary cholesterol. Scand J Gastroenterol,2009,44(4):471-477.
[26] Ryan MC,Itsiopoulos C,Thodis T,et al.The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol,2013,59(1):138-143.
[27] Arab J P,Candia R,Zapata R,et al.Management of nonalcoholic fatty liver disease:an evidence-based clinical practice review. World J Gastroenterol,2014,20(34):12182-12201.
[28] Oh S,Shida T,Yamagishi K,et al.Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease:a retrospective study. Hepatology,2015,61(4):1205-1215.
[29] Vilar-Gomez E,Martinez-Perez Y,Calzadilla-Bertot L,et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology,2015,149(2):367-378,e14-e15.
[30] PLassailly G,Caiazzo R,Buob D,et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology,2015,149(2):379-388,e15-e16.
[31] Vilargomez E,Martinezperez Y,Calzadillabertot L,et al.Weight loss via lifestyle modification significantly reduces features of nonal-
coholic steatohepatitis. Gastroenterology,2015,149(2),367-378.
[32] Nergard BJ,Lindqvist A,Gislason HG,et al.Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide cell numbers in the super-obese human foregut after gastric bypass. Surg Obes Relat Dis,2015,11(6):1237-1246.
[33] Moscatiello S,Di Luzio R,Bugianesi E,et al.Cognitive-behavioral treatment of nonalcoholic Fatty liver disease:a propensity score-adjusted observational study. Obesity (Silver Spring),2011,19(4):763-770.
[34] 中华医学会内分泌学分会肝病与代谢学组. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识. 中华内分泌代谢杂志,2010,26(7):531-534.
[35] Ahn JS,Sinn DH,Son HJ,et al.Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia-authors' reply. Aliment Pharmacol Ther,2017,45(4):577-578.
[36] Wong RJ,Cheung R,Ahmed A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology,2014,59(6):2188-2195.